CBD vs THC: what patients actually need to know

Almost every conversation about medicinal cannabis comes down to two molecules: THC and CBD. They are often spoken of as two flavours of the same thing. They are not. They behave very differently in the body, carry different risks, and suit different situations — and understanding the contrast helps you make sense of what your prescriber recommends.

THC — the intoxicating one

THC (delta-9-tetrahydrocannabinol) is the compound responsible for cannabis's "high." Pharmacologically it is a partial agonist at the body's CB1 and CB2 receptors; its action on CB1 receptors in the brain drives the intoxicating effects.

Typical effects include euphoria, altered perception, relaxation, increased appetite and a faster heart rate. At higher doses, or in vulnerable people, THC can cause anxiety, paranoia, impaired concentration and short-term memory, and can worsen psychotic symptoms. Because it is intoxicating, THC is dose-limiting — prescribers move in small milligram steps and keep daily totals relatively low (often in the tens of milligrams).

The better-supported uses for THC-based products include chemotherapy nausea, MS spasticity (combined with CBD), and chronic and neuropathic pain — though for pain the demonstrated effect is generally small.

CBD — the non-intoxicating one

CBD (cannabidiol) does not get you high. A common myth is that CBD works by activating the same receptors as THC; it does not meaningfully activate CB1's main binding site. Its pharmacology is "promiscuous," touching dozens of different targets — it acts as a negative allosteric modulator at CB1 (which can blunt some of THC's effects), and engages serotonin 5-HT1A receptors, TRPV channels, PPARγ and others.

CBD has the strongest evidence of any cannabinoid, but in a narrow place: purified CBD (Epidiolex/Epidyolex) is approved for seizures in rare childhood epilepsies. Because it is non-intoxicating, CBD is dosed far higher than THC and is favoured where impairment must be avoided — for example in occupational settings or where anxiety is a concern.

A side-by-side summary:

	THC	CBD
Intoxicating?	Yes	No
Main concern	Anxiety, sedation, fast heart rate, cognitive effects, abuse potential	Mild: GI upset, drowsiness, liver-enzyme rises at high doses
Strongest evidence	Chemotherapy nausea; MS spasticity (with CBD)	Rare childhood epilepsies
Dosed	Low, in small steps	Higher

Why ratio matters more than ingredient

In practice, prescribers rarely think in terms of "CBD or THC" — they think in terms of ratio. Products are broadly grouped as CBD-dominant, balanced (around 1:1), and THC-predominant. The ratio is the lever used to balance benefit against intoxication and tolerability:

• CBD-dominant where non-intoxication is essential.
• Balanced (1:1) for conditions like MS spasticity (Sativex is roughly 1:1) and some pain.
• THC-predominant where THC's effect is central and the patient tolerates it.

The "CBD cancels out THC" myth

You will often read that CBD simply neutralises THC's downsides. That is an oversimplification. CBD can blunt some of THC's unwanted effects — intoxication, fast heart rate, anxiety — but this is dose- and route-dependent and not absolute. One controlled study of edibles even found that CBD did not reliably reduce, and on some measures increased, THC's adverse effects. Treat "CBD makes THC safe" as a marketing simplification, not a guarantee.

What about the "minor" cannabinoids?

You will increasingly see products and marketing referencing minor cannabinoids — CBG, CBN, CBC, THCV. It's worth a reality check: for almost all of these, the evidence in humans is essentially absent. The popular belief that CBN is a powerful sleep aid, for instance, is largely a myth; it traces back to anecdote and a decades-old rat study, with no real human data behind it. CBG, CBC and THCV are interesting in the laboratory but remain preclinical. Treat strong claims about minor cannabinoids as hypotheses, not established medicine.

The same caution applies to the "entourage effect" — the appealing idea that cannabinoids, terpenes and flavonoids work better together. It's biologically plausible and actively studied, but there are no clinical trials designed to validate it, and the term is frequently used for marketing. One narrow human finding does stand out: a controlled trial suggested the terpene D-limonene can reduce THC-induced anxiety. That supports one specific interaction, not broad synergy.

Side effects, compared

The two cannabinoids differ here too. THC's side effects are dose-limiting and can include anxiety, a fast heart rate, sedation and cognitive effects, and it carries some abuse potential. CBD's side effects are generally milder — drowsiness, diarrhoea, reduced appetite, and rises in liver enzymes at the high doses used in pharmaceutical products — and the World Health Organization has found no abuse signal for it. This difference is a big part of why prescribers reach for CBD where avoiding impairment matters most.

The bottom line for patients

THC and CBD are different medicines with different risk profiles, and the art of prescribing lies in the ratio and the dose — chosen for your condition, your goals and your tolerance. Don't fixate on a single ingredient; the question your prescriber is really answering is "what balance, at what dose, for you?"

Last reviewed 13 July 2026 — education, not medical advice. Sources: WHO CBD review 2018; Pertwee 2008 — cannabinoid pharmacology; Johns Hopkins 2023 — CBD and THC in edibles.